BioLineRx
BioLineRx is an Israel-based clinical stage biopharmaceutical company that researches and develops novel therapeutics for the treatment of cancer.
Business Model:
Revenue: $900k
Employees: 11-50
Industries / Tags:
Detailed BioLineRx Information
Geographic Data
Address: 2 HaMa’ayan Street
City: Tel Aviv
State: tel aviv district
Zip: 7177871
Country: IL
Financial Info
Stage:
post ipo equity
Raised Last:
$35M
Raised Total:$176M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
BioLineRx is an Israel-based clinical stage biopharmaceutical company that researches and develops novel therapeutics for the treatment of cancer.
Contact Phone:
Contact Email:
BioLineRx went public on 8/5/2011 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
8/5/2011
Ticker Symbol:
BLRX
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2004 | Venture Round | 2 | $4M |
Yehuda Zisapel Star Ventures Yehuda Zisapel Star Ventures |
6/2020 | Unattributed | $4.4M |
Cross Atlantic Capital Partners Forbion Capital Partners |
7/2017 | Post-IPO Equity | 1 | $9.6M |
Biotechnology Value Fund Biotechnology Value Fund Biotechnology Value Fund Biotechnology Value Fund |
3/2014 | Post-IPO Equity | $24.1M | 5/2020 | Unattributed | $9M |
Cross Atlantic Capital Partners Forbion Capital Partners |
9/2022 | Post-IPO Debt | $40M |
Kreos Capital |
2/2012 | Post-IPO Equity | $15M | 5/2020 | Post-IPO Equity | $13.4M | 3/2015 | Post-IPO Equity | $25M | 3/2017 | Post-IPO Equity | $28.8M | 2/2013 | Post-IPO Equity | 1 | $8M |
OrbiMed OrbiMed |
9/2022 | Post-IPO Equity | $15M | 9/2005 | Venture Round | $0 |
Teva Pharmaceutical Industries Pitango VC Giza Venture Capital Teva Pharmaceutical Industries Pitango VC Giza Venture Capital |
9/2022 | Post-IPO Debt | 1 | $10M |
Kreos Capital Kreos Capital |
1/2021 | Post-IPO Equity | $34.5M | 12/2014 | Post-IPO Equity | 1 | $10M |
Novartis Novartis |
2/2019 | Post-IPO Equity | $15.4M | 5/2020 | Unattributed | $4.4M |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 3/2017 | Agalimmune |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
